DYNE THERAPEUTICS INC(NASDAQ:DYN) stock Fundamental Analysis

Fundamental Rating

DYN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DYN as it has an excellent financial health rating, but there are worries on the profitability. DYN does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

DYN had negative earnings in the past year.

In the past year DYN has reported a negative cash flow from operations.

In the past 5 years DYN always reported negative net income.

DYN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of DYN (-45.92%) is comparable to the rest of the industry.

DYN's Return On Equity of -50.40% is fine compared to the rest of the industry. DYN outperforms 64.90% of its industry peers.

		Industry Rank	Sector Rank
ROA	-45.92%
ROE	-50.4%
ROIC	N/A

ROA(3y)-81.24%

ROA(5y)-59.12%

ROE(3y)-125.15%

ROE(5y)-86.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

DYN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, DYN has more shares outstanding

Compared to 5 years ago, DYN has more shares outstanding

DYN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 9.79 indicates that DYN is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 9.79, DYN belongs to the top of the industry, outperforming 88.18% of the companies in the same industry.

There is no outstanding debt for DYN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	9.79

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

DYN has a Current Ratio of 15.60. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 15.60, DYN belongs to the best of the industry, outperforming 91.36% of the companies in the same industry.

DYN has a Quick Ratio of 15.60. This indicates that DYN is financially healthy and has no problem in meeting its short term obligations.

DYN has a better Quick ratio (15.60) than 91.36% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.6
Quick Ratio	15.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

DYN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.97%, which is quite good.

EPS 1Y (TTM)14.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.27%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DYN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.17% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-8.65%

EPS Next 2Y-6.43%

EPS Next 3Y3.48%

EPS Next 5Y15.17%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

DYN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DYN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-6.43%

EPS Next 3Y3.48%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for DYN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DYNE THERAPEUTICS INC

NASDAQ:DYN (4/25/2025, 8:02:40 PM)

After market: 11.06 0 (0%)

11.06

-0.05 (-0.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-27 2025-02-27/bmo

Earnings (Next)05-01 2025-05-01/amc

Inst Owners109.43%

Inst Owner Change0.01%

Ins Owners0.74%

Ins Owner Change2.08%

Market Cap1.26B

Analysts85.56

Price Target51.63 (366.82%)

Short Float %10.24%

Short Ratio5.23

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-12.08%

Min EPS beat(2)-33.5%

Max EPS beat(2)9.33%

EPS beat(4)2

Avg EPS beat(4)-5.24%

Min EPS beat(4)-33.5%

Max EPS beat(4)9.33%

EPS beat(8)2

Avg EPS beat(8)-11.16%

EPS beat(12)5

Avg EPS beat(12)-5.7%

EPS beat(16)6

Avg EPS beat(16)-5.21%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-1.8%

PT rev (3m)0.39%

EPS NQ rev (1m)0.46%

EPS NQ rev (3m)5.46%

EPS NY rev (1m)0.61%

EPS NY rev (3m)6.68%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2
P/tB	2
EV/EBITDA	N/A

EPS(TTM)-3.35

EYN/A

EPS(NY)-3.64

Fwd EYN/A

FCF(TTM)-2.59

FCFYN/A

OCF(TTM)-2.57

OCFYN/A

SpS0

BVpS5.54

TBVpS5.54

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-45.92%
ROE	-50.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-81.24%

ROA(5y)-59.12%

ROE(3y)-125.15%

ROE(5y)-86.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	142.02%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	15.6
Quick Ratio	15.6
Altman-Z	9.79

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)122.78%

Cap/Depr(5y)173.23%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)14.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.27%

EPS Next Y-8.65%

EPS Next 2Y-6.43%

EPS Next 3Y3.48%

EPS Next 5Y15.17%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-42.01%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-17.05%

EBIT Next 3Y-6.41%

EBIT Next 5YN/A

FCF growth 1Y-56.04%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-55.38%

OCF growth 3YN/A

OCF growth 5YN/A

DYNE THERAPEUTICS INC (DYN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens